- Home
- MCHB vs XENE Comparison
MCHB vs XENE Comparison
Compare MCHB & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCHB | XENE |
|---|---|---|
| Founded | 1905 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MCHB | XENE |
|---|---|---|
| Price | $14.70 | $39.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 18 |
| Target Price | $16.25 | ★ $71.75 |
| AVG Volume (30 Days) | 613.5K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 10.65% | N/A |
| EPS Growth | ★ 116.60 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $49,728,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.85 | $2,045.70 |
| P/E Ratio | $32.67 | ★ N/A |
| Revenue Growth | ★ 3.33 | N/A |
| 52 Week Low | $13.02 | $33.38 |
| 52 Week High | $17.38 | $72.66 |
Technical Indicators
Market Signals| Indicator | MCHB | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 50.16 |
| Support Level | $14.51 | $33.38 |
| Resistance Level | $15.44 | $39.92 |
| Average True Range (ATR) | 0.40 | 1.26 |
| MACD | 0.02 | 0.89 |
| Stochastic Oscillator | 41.38 | 77.62 |
Price Performance
Historical ComparisonAbout MCHB Mechanics Bancorp
Mechanics Bancorp is the financial holding company of Mechanics Bank, a full-service bank with branches across California, Oregon, Washington and Hawaii. It offers a various products and services in consumer and business banking, commercial lending, cash management services, private banking, and comprehensive wealth management and trust services.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.